FORT LEE, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced that new details of the company's landmark, randomized, double-blind Phase 2 clinical trial of NLX-P101, its investigational gene therapy for advanced Parkinson's disease (PD), were presented during a symposium at the 2nd World Parkinson Congress in Glasgow, Scotland. Co-principal investigator of the trial, Dr. Peter Lewitt, Director of the Parkinson's Disease and Movement Disorders program at Henry Ford Hospital, reported that, in addition to statistically significant improvements over the entire blinded study period in the off-medication motor scores between the treated and sham groups on the Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 (Motor section), 75 percent of patients in the treatment group were considered to have had a meaningful response to NLX-P101 (i.e., a five point or greater reduction in the off-medication UPDRS motor scores), which is comparable to the response rate of 71 percent in a recent study of Deep Brain Stimulation (Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson's disease: a randomized controlled trial. JAMA 2009; 301:63-73).
Dr. Lewitt also emphasized that results showed a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported. Although details regarding the study methodology were also provided, such as catheter placement in the subthalamic nucleus (STN), specific quantitative outcomes were not discussed during the presentation, as these will be presented in a peer-reviewed publication, currently under review.
Earlier this year, Neurologix disclosed top-line results for this Phase 2 trial, announcing that study participants who received NLX-P101 ex